BeyondSpring Inc. (BYSI)
| Market Cap | 57.36M -20.6% |
| Revenue (ttm) | n/a |
| Net Income | -7.64M |
| EPS | -0.19 |
| Shares Out | 41.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,029 |
| Open | 1.300 |
| Previous Close | 1.360 |
| Day's Range | 1.300 - 1.532 |
| 52-Week Range | 1.210 - 3.440 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 1.25 (-10.39%) |
| Earnings Date | May 13, 2026 |
About BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company’s lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropen... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for BYSI stock is "Strong Buy" and the 12-month stock price target is $1.25.
News
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment ...
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Mol...
BeyondSpring Earnings release: Q1 2026
BeyondSpring released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
BeyondSpring Quarterly report: Q1 2026
BeyondSpring has published its Q1 2026 quarterly earnings report on May 13, 2026.
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy
BeyondSpring Slides: Corporate presentation
BeyondSpring has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
BeyondSpring Files 2025 Annual Report on Form 10-K
FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatmen...
BeyondSpring Annual report: Q4 2025
BeyondSpring has published its Q4 2025 annual report on March 25, 2026.
BeyondSpring Earnings release: Q4 2025
BeyondSpring released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today a...
BeyondSpring presents Phase 3 DUBLIN-3 data at ESMO Asia Congress
BeyondSpring (BYSI) announced results from the Asian subset of its global Phase 3 DUBLIN-3 trial evaluating Plinabulin plus docetaxel compared to docetaxel alone in second- or third-line EGFR wild-typ...
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today a...
BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC
BeyondSpring (BYSI) announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study showing that Plinabulin plus docetaxel provides clinically meaningful benefit for patients with EGFR wild-typ...
BeyondSpring reports Q3 EPS (4c) vs (5c) last year
“With over 700 patients treated, Plinabulin continues to demonstrate a favorable safety profile and meaningful potential as an immune-modulating therapy with unique mechanism of dendritic cell (DC) ma...
BeyondSpring Quarterly report: Q3 2025
BeyondSpring has published its Q3 2025 quarterly earnings report on November 12, 2025.
BeyondSpring Earnings release: Q3 2025
BeyondSpring released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
BeyondSpring reports Q2 EPS (10c) vs (4c) last year
“At the heart of BeyondSpring’s (BYSI) pipeline is Plinabulin, a first-in-class agent potentially redefining cancer treatment by harnessing the body’s own immune system,” said Dr. Lan Huang, Co-Founde...
BeyondSpring Quarterly report: Q2 2025
BeyondSpring has published its Q2 2025 quarterly earnings report on August 13, 2025.
BeyondSpring Earnings release: Q2 2025
BeyondSpring released its Q2 2025 earnings on August 13, 2025, summarizing the period's financial results.
BeyondSpring Proxy statement: Proxy Filing
BeyondSpring filed a proxy statement on August 6, 2025, providing details for shareholder voting and corporate governance matters.
BeyondSpring Proxy statement: Proxy Filing
BeyondSpring filed a proxy statement on August 6, 2025, providing details for shareholder voting and corporate governance matters.
BeyondSpring announces publication of human clinical study on plinabulin
BeyondSpring (BYSI) announced publication of a human clinical study in Med demonstrating that Plinabulin, when combined with radiation and a checkpoint inhibitor, induces dendritic cell maturation and...
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
FLORHAM PARK, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) today announced publication of a human clinical study in Med (Cell Press) demonstrating that Plinabulin, when com...
BeyondSpring presents interim phase 2 data on 303 study
BeyondSpring (BYSI) announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer, NSCLC, after disease progression on 1L PD-1/L1 inhibitors…
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer...